Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) (NCT06545682)

🧪 Interventions in This Study

• Alpelisib + Pembrolizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• MD Anderson Cancer Center — Houston, Texas

📞 Contact the Study Coordinator

Phone: (713) 792-3934

Email: eeileana@mdanderson.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Melanoma (Skin Cancer)

• A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma — Nashville, Tennessee
• Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade — New York, New York
• NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma — Chapel Hill, North Carolina
• Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors — Tucson, Arizona
• Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions — Chicago, Illinois

Explore by condition: All Melanoma (Skin Cancer) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.